ClinicalTrials.gg
CompletedNCT05484206Updated Sep 9, 2026

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

A Phase 1 interventional study of VIR-2218 and VIR-3434 in Hepatic Impairment and Cirrhosis, sponsored by Vir Biotechnology, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Vir Biotechnology, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 415 studies in Fibrosis with a site in United States — 81 open to participants now, 109 under way, 13 of them phase 3. Fibrosis · United States.

Enrollment
121st of 330
88 · median 52
Started
2022
with 17 others
Phase 1
43 of 415
7 open now
Registered
328th of 415
by date

Among the 415 studies in Fibrosis with a site in United States, this one is the 121st largest by enrollment of the 330 interventional ones that give a count, is one of 18 that started in 2022, is one of 43 in phase 1, and was the 328th registered.

Fibrosis

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

Browse Fibrosis studies →

Open to participants now

81 of the 415 studies in Fibrosis with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Fibrosis with a site in United States, or all of them as a file.
02

Study summary

In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.

Read the detailed description

Participants may be enrolled in Cohorts 1, 2, 3, 4, 5, 6, 7, 8, and 9 in a non-randomized way.

03

Conditions studied

  • Hepatic Impairment
  • Cirrhosis

Browse trials for

Keywords

  • siRNA
  • Monoclonal antibody
  • HDV
  • Compensated Cirrhosis
  • Decompensated Cirrhosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥18 to ≤70 years of age at screening
  • Must have a calculated from 18.5 ≤ BMI ≤ 40 kg/m2
  • All participants must have an ≥ 60 mL/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation

Inclusion criteria: Healthy matched participants

  • Must in the opinion of the Investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations

Inclusion criteria: Hepatic impaired participants

  • Apart from hepatic insufficiency, participants must, in the opinion of the Investigator be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations
  • Participant is considered to have chronic, stable moderate, severe, mild HI (of any etiology excluding chronic and HDV) and has been clinically stable per Investigator assessment for at least 1 month prior to screening
  • CPT score of 5 to 6 for mild HI at screening
  • CPT score 7-9 for moderate HI at screening
  • CPT score 10-15 severe HI at screening

Exclusion criteria

Exclusion Criteria:

  • Participants with unstable cardiac function or evidence of previous myocardial infarction in the past 12 months or any active cardiovascular disease that, in the opinion of the Investigator, could interfere with the safety of the participant
  • Any clinically significant conduction abnormality or arrhythmia (including non-sustained or sustained ventricular tachycardia as per Investigator's assessment)
  • Infection with (HIV), hepatitis A virus (HAV), (positive HBsAg or positive hepatitis B core antibody with negative hepatitis B surface antibody), virus (HCV), HDV or hepatitis E virus (HEV). HCV antibody positive participants with a negative HCV RNA are eligible. HDV antibody positive participants with a negative HDV RNA are eligible

Exclusion criteria: Healthy matched participants

  • Systolic BP is outside the range of 90-160 mmHg, or diastolic BP is outside the range of 45-95 mmHg or heart rate is outside the range of 50-100 beats per minute (bpm) for female participants or 45-100 bpm for male participants at screening
  • Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal medication) within 30 days prior to D1 of study participation

Exclusion criteria: Participants with Hepatic impairment

  • Not on stable dose and regimen of any medication
  • Acute or worsening chronic hepatitis
  • Participants requiring paracentesis more than once a month
  • Participants with encephalopathy or significant Central Nervous System
  • History of gastric or esophageal variceal bleeding within the past 6 months
  • Participants with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement
  • Presence of hepatopulmonary or hepatorenal syndrome
  • Presence of primarily cholestatic liver diseases
  • History of or currently listed for liver transplantation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Cohort 1: CPT-B (moderate HI) participants and matched healthy participants will be evaluated first

    All participants in Cohort 1 will be receiving VIR-2218 monotherapy.

    Drug: VIR-2218

  • Experimental
    Cohort 2: CPT-C (severe HI) participants and matched healthy participants

    This arm is optional based on Cohort 1. All participants in Cohort 2 will be receiving VIR-2218 monotherapy.

    Drug: VIR-2218

  • Experimental
    Cohort 3: CPT-A (mild HI) participants and matched healthy participants

    This cohort is optional. All participants in Cohort 3 will be receiving VIR-2218 monotherapy.

    Drug: VIR-2218

  • Experimental
    Cohort 4: CPT-A (mild HI) participants and matched healthy participants

    All participants in Cohort 4 will be receiving VIR-3434 monotherapy.

    Drug: VIR-3434

  • Experimental
    Cohort 5: CPT-B (moderate HI) participants and matched healthy participants

    All participants in Cohort 5 will be receiving VIR-3434 monotherapy.

    Drug: VIR-3434

  • Experimental
    Cohort 6: CPT-C (severe HI) participants and matched healthy participants

    This arm is optional based on Cohort 5. All participants in Cohort 6 will be receiving VIR-3434 monotherapy.

    Drug: VIR-3434

  • Experimental
    Cohort 7: CPT-A (mild HI) and matched healthy participants

    All participants in Cohort 7 will be receiving VIR-3434 and VIR-2218 combination therapy.

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 8: CPT-B (moderate HI) and matched healthy participants

    All participants in Cohort 8 will be receiving VIR-3434 and VIR-2218 combination therapy.

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 9: CPT-C (severe HI) and matched healthy participants

    This arm is optional based on Cohort 8. All participants in Cohort 9 will be receiving VIR-3434 and VIR-2218 combination therapy.

    Drug: VIR-2218 · Drug: VIR-3434

Interventions

  • VIR-2218 given by subcutaneous injection.

  • VIR-3434 given by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218

    Time frame: 5 days

  2. Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR2218

    Time frame: 5 days

  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR2218

    Time frame: 5 days

  4. Maximum observed Plasma concentration (Cmax) of VIR-3434

    Time frame: 18 weeks

  5. Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-3434

    Time frame: 18 weeks

  6. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-3434

    Time frame: 18 weeks

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Up to 18 Weeks

  2. Incidence of ADA and titers of ADA to VIR-3434 at each study visit for cohorts receiving VIR-3434 therapy

    Time frame: 18 Weeks

07

Study locations

4 sites
  • Inland Empire Clinical Trials
    Rialto, California 92377, United States
  • Orange County Research Center
    Tustin, California 92790, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2025, 38 months.

Of 41 phase 1 interventional studies under Fibrosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 58. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2022
First posted
Aug 2, 2022
StartActual
Sep 21, 2022
Primary completionActual
Dec 9, 2025
CompletionActual
Dec 9, 2025
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05484206
Responsible party
Sponsor
First posted
Aug 2, 2022
Start date
Sep 21, 2022
Primary completion
Dec 9, 2025
Completion
Dec 9, 2025
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elebsiran · Tobevibart

Start the discussion